Contract 75A50123C00010
Albert B. Sabin Vaccine Institute, Inc. (The) · Department Of Health And Human Services · December 29, 2022
Albert B. Sabin Vaccine Institute, Inc. (The) was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on December 29, 2022 for $158.81 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Washington, DC. It was awarded under full and open competition. The contract has been modified 12 times since the base award It uses cost-plus contract pricing. The most recent modification was on July 29, 2025. If all options are exercised, the contract could reach $238.38 million.
Contract details
- PIID
- 75A50123C00010
- Award type
- Definitive Contract
- Pricing
- Cost Plus Fixed Fee
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care - Other; Applied Research
- Place of performance
- Washington, DC
- First action
- December 29, 2022
- Latest action
- July 29, 2025
Description
THE PURPOSE OF THIS MODIFICATION IS TO 1. EXERCISE OPTION PERIOD 2 CLIN 0003 WITH A PERIOD OF PERFORMANCE OF JULY 22, 2025, TO DECEMBER 28, 2032, IN THE AMOUNT OF $38,697,183.73. AS A RESULT OF TH
Modification timeline
-
July 29, 2025Mod P00012THE PURPOSE OF THIS MODIFICATION IS TO 1. EXERCISE OPTION PERIOD 2 CLIN 0003 WITH A PERIOD OF PERFORMANCE OF JULY 22, 2025, TO DECEMBER 28, 2032, IN THE AMOUNT$38.70M
-
July 8, 2025Mod P00011THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0008 (OPTION 7) THE TOTAL UNEXERCISED VALUE IS HEREBY DECREASED FROM $8,443,038.00 BY $1,554,748.99 TO $$1.55M
-
May 1, 2025Mod P00010THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0001/ BASE: INCREASE THE FUNDING FROM $52,015,534.00 BY $4,695,621.32 TO $56,711,155.32 TO FACILITATE TH$13.08M
-
January 10, 2025Mod P00009THE PURPOSE OF THIS NO COST MODIFICATION IS TO DONATE 188 VIALS OF SUDV CLINICAL TRIAL MATERIAL FOR THREE NONCLINICAL STUDIES AS FOLLOWS: 1. CLIN 0001 (BASE PER$0
-
December 16, 2024Mod P00008THE PURPOSE OF THIS MODIFICATION IS HEREBY AMENDED AS FOLLOWS: 1. CLIN 0001 (BASE PERIOD) IS HEREBY AMENDED AS FOLLOWS: A. AN ADDITIONAL $17,053,156 IN FUNDS AR$17.05M
-
October 10, 2024Mod P00007THE PURPOSE OF THIS NO COST MODIFICATION IS TO ADD AN AUDIT OF REITHERA SRL TO THE SCOPE OF CLIN 0005 AS FOLLOWS: 1. CLIN 0005 (OPTION 4) IS HEREBY AMENDED AS F$0
-
September 25, 2024Mod P00006THE PURPOSE OF THIS MODIFICATION IS TO CHANGE PRODUCTION UNDER CLIN 0005 AND CLIN 0006 AND EXTEND THE PERIOD OF PERFORMANCE ON CLIN 0005 AS FOLLOWS: 1. CLIN 000$17.03M
-
August 23, 2024Mod P00005THE PURPOSE OF THIS NO COST MODIFICATION IS TO INCORPORATE AN UPDATED STATEMENT OF WORK AMENDING THE VERBIAGE AS FOLLOWS: 1. CLIN 0001 IS HEREBY AMENDED PERFORM$0
-
July 16, 2024Mod P00004THE PURPOSE OF THIS $0 MODIFICATION IS TO: 1. CLIN 0001 IS HEREBY AMENDED TO INCLUDE AN ADDITIONAL 4TH DS BATCH RUN OF SUDV, AND TO REFLECT THE INCREASE OF REIT$0
-
May 16, 2024Mod P00003THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE D$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | The Boeing Company | 1 | $4.44B |
| 2 | Advanced Technology International | 9 | $3.35B |
| 3 | Amgen USA Inc | 2 | $774.69M |
| 4 | Siga Technologies, Inc. | 1 | $624.44M |
| 5 | Icon Government And Public Health Solutions, Inc. | 16 | $404.80M |
| 6 | Technical Resources International, Inc. | 19 | $395.29M |
| 7 | Allucent Government Services (Us) Llc | 9 | $384.26M |
| 8 | Mapp Biopharmaceutical, Inc. | 7 | $354.24M |
| 9 | Ppd Development Lp | 18 | $331.02M |
| 10 | Albert B. Sabin Vaccine Institute, Inc. (The) | 2 | $305.87M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50123C00010?
Contract 75A50123C00010 is a federal contract awarded to Albert B. Sabin Vaccine Institute, Inc. (The) by Department Of Health And Human Services on December 29, 2022 for $158.81 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 12 times since the base award.
Who won contract 75A50123C00010?
Albert B. Sabin Vaccine Institute, Inc. (The) won contract 75A50123C00010 from Department Of Health And Human Services.
How much is contract 75A50123C00010 worth?
Contract 75A50123C00010 has obligated $158.81 million to date, with a total potential value of $238.38 million if all options are exercised.